Fwd: [Systemic treatment of non-small cell lung cancer - recommendations based on the results of reliable clinical trials.]

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Fri, Feb 22, 2008 at 10:18 AM
Subject: [Systemic treatment of non-small cell lung cancer - recommendations based on the results of reliable clinical trials.]
To: mesothelioma77@gmail.com


[1]Pneumonol Alergol Pol. 2008; 76(1): 44-52
Jassem J, Drosik K, Dziadziuszko R, Kordek R, Kozielski J, Kowalski D, Krzakowski M, Nikliński J, Olszewski W, Orłowski T, Ramlau R, Roszkowski-Śliż K

Lung cancer is in Poland the most common malignancy. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung tumors. In the multidisciplinary treatment of non-small cell lung cancer patients the role of chemotherapy and, most recently, molecular targeted therapy is increasing. In 2005 we published recommendations for systemic treatment of non-small cell lung cancer and mesothelioma. As many new studies have been published since, it was necessary to update this document. We present here a consensus statement on this topic, prepared by a panel of experts in oncology, thoracic surgery, pathology and pneumonology.



___
Source: http://www.hubmed.org/display.cgi?uids=18283654
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc